Camille L. Bedrosian - Sep 1, 2021 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP and Chief Medical Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Sep 1, 2021
Transactions value $
-$225,525
Form type
4
Date filed
9/2/2021, 06:11 PM
Previous filing
Jun 23, 2021
Next filing
Oct 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Options Exercise $138K +2.5K +6.45% $55.00 41.3K Sep 1, 2021 Direct F1
transaction RARE Common Stock Sale -$250K -2.5K -6.06% $100.03 38.8K Sep 1, 2021 Direct F2
transaction RARE Common Stock Options Exercise $138K +2.5K +6.45% $55.00 41.3K Sep 2, 2021 Direct
transaction RARE Common Stock Sale -$250K -2.5K -6.06% $100.18 38.8K Sep 2, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Options Exercise $0 -2.5K -4.31% $0.00 55.5K Sep 1, 2021 Common Stock 2.5K $55.00 Direct F4
transaction RARE Stock Option (Right to Buy) Options Exercise $0 -2.5K -4.5% $0.00 53K Sep 2, 2021 Common Stock 2.5K $55.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date.